Silence Therapeutics (SLN) risk factors
Item 1A of every Silence Therapeutics plc 10-K on file, and what changed from one year to the next. Readings are automated and can be wrong; check the filing for the exact wording.
- FY2025 10-K risk factors75 risks9 new6 dropped14 reworded
Cash and cash equivalents and U.S. treasury bills decreased from $147.3 million to $85.1 million as of December 31, 2025. Cumulative U.K. carryforward tax losses reached $231.6 million as of December 31, 2025. The U.K. Takeover Code residency test will be abolished on February 3, 2027.
Filed Mar 05, 2026 - FY2024 10-K risk factors72 risks
Silence Therapeutics relies entirely on unproven siRNA technology with no commercial products and a history of significant net losses. Operations depend heavily on partnerships with companies like AstraZeneca, Hansoh, and Mallinckrodt. Capital requirements are high, supported by $147.3 million in cash as of December 31, 2024.
Filed Feb 27, 2025